open access

Vol 53, No 3 (2015)
Original paper
Submitted: 2015-07-10
Accepted: 2015-09-22
Published online: 2015-09-24
Get Citation

Comparative analysis of CD4 and CD8 lymphocytes — evidences for different distribution in primary and secondary liver tumors

Simona E. Giuşcă, Piotr M. Wierzbicki, Cornelia Amălinei, Irina-Draga Căruntu, Elena R. Avădănei
DOI: 10.5603/fhc.a2015.0027
·
Pubmed: 26484587
·
Folia Histochem Cytobiol 2015;53(3):272-281.

open access

Vol 53, No 3 (2015)
ORIGINAL PAPERS
Submitted: 2015-07-10
Accepted: 2015-09-22
Published online: 2015-09-24

Abstract

Introduction. The impact of tumor cells on tumor-infiltrating lymphocytes (TILs) in cancer development is not yet clarified. Our study analyzed the distribution and prognostic value of CD4+ and CD8+ T lymphocytes in hepatocellular carcinoma (HCC) and liver metastases (LM).

Material and methods. Archival tissue specimens of 35 HCC and 39 LM patients were immunohistochemically processed. The number of intratumoral (IT) and peritumoral (PT) CD4+ and CD8+ T cells was quantitatively analyzed.

Results. We noted large variances of T lymphocyte subpopulations. Similar number of CD4+ and CD8+ lym­phocytes was present in HCC, whereas in LM the number of CD8+ cells was approximately two times higher than CD4+ lymphocytes. A significant prevalence of T cells in PT over IT areas was observed. The prognostic value was demonstrated only for PT CD8+ lymphocytes in LM, their reduced number being associated with shorter survival.

Conclusions. The differences between proportions of T lymphocytes within tumor and its environment might be explained by proapoptotic effect of cancer cells on TILs.

Abstract

Introduction. The impact of tumor cells on tumor-infiltrating lymphocytes (TILs) in cancer development is not yet clarified. Our study analyzed the distribution and prognostic value of CD4+ and CD8+ T lymphocytes in hepatocellular carcinoma (HCC) and liver metastases (LM).

Material and methods. Archival tissue specimens of 35 HCC and 39 LM patients were immunohistochemically processed. The number of intratumoral (IT) and peritumoral (PT) CD4+ and CD8+ T cells was quantitatively analyzed.

Results. We noted large variances of T lymphocyte subpopulations. Similar number of CD4+ and CD8+ lym­phocytes was present in HCC, whereas in LM the number of CD8+ cells was approximately two times higher than CD4+ lymphocytes. A significant prevalence of T cells in PT over IT areas was observed. The prognostic value was demonstrated only for PT CD8+ lymphocytes in LM, their reduced number being associated with shorter survival.

Conclusions. The differences between proportions of T lymphocytes within tumor and its environment might be explained by proapoptotic effect of cancer cells on TILs.

Get Citation

Keywords

hepatocellular carcinoma; liver metastases; Th cells; Tc cells; prognostic factors

About this article
Title

Comparative analysis of CD4 and CD8 lymphocytes — evidences for different distribution in primary and secondary liver tumors

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 53, No 3 (2015)

Article type

Original paper

Pages

272-281

Published online

2015-09-24

DOI

10.5603/fhc.a2015.0027

Pubmed

26484587

Bibliographic record

Folia Histochem Cytobiol 2015;53(3):272-281.

Keywords

hepatocellular carcinoma
liver metastases
Th cells
Tc cells
prognostic factors

Authors

Simona E. Giuşcă
Piotr M. Wierzbicki
Cornelia Amălinei
Irina-Draga Căruntu
Elena R. Avădănei

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl